The use of vasoactive therapy for acute decompensated heart failure: Hemodynamic and renal considerations

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 5, 2007, Pages

  Heywood, J Thomas ^a   Khan, Tariq A ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

B type natriuretic peptide; Heart failure; Renal insufficiency

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMRINONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; HYPERTENSIVE AGENT; INOTROPIC AGENT; ISOPRENALINE; METOLAZONE; MILRINONE; NESIRITIDE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE; VASOACTIVE AGENT; VASODILATOR AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TRANSFORMATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MORTALITY; PROTEINURIA; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; CARDIAC OUTPUT; CARDIOTONIC AGENTS; HEART FAILURE; HEMODYNAMICS; HUMANS; KIDNEY; MILRINONE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NITRATES; SYMPATHOMIMETICS; VASODILATOR AGENTS;

EID: 38349076667     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Hasselblad V, Stough WG, Shah MR, et al. Relationship between dose of loop diuretics and outcomes in a heart failure population: Results of ESCAPE Trial. Eur J Heart Fail. 2007;9:1064-1069.
2. HFSA 2006 Comprehensive Heart Failure Practice Guideline, J Card Fail. 2006;12:1-2.
3. Adams KF Jr, Fonarow GC, Emerman CI, et al. Characteristics and outcome of patients hospitalized for heart failure in United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompen-sated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
4. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management and inhospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006; 47:76-84.
5. Fonarow GC, Stough WG, Abrahm WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50:768-777.
6. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. JAMA. 2007;297:1883-1891.
7. Konstam M, Gheorghiade M, Burnett JC, et al. Effect of oral tolvaptan in patients hospitalized for worsening heart failure The EVEREST outcome trial. JAMA. 2007;297:1319-1331.
8. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure (OPTIME-CHF) investigators. JAMA. 2002;287:1541-1547.
9. Fonarow GC, Adams KF Jr, Abraham WT, et al; for the ADHERE scientific advisory committee study group and investigators. Risk stratification for in-hospital mortality in acute decompensated heart failure. JAMA. 2005;293:572-580.
10. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its on outcome in 118,465 patients hospitalized with acute decompansated heart failure: a report from ADHERE database. J Card Fail. 2007; 13:422-430.
11. Stevenson LW. Clinical use of inotropic therapy for heart failure: Looking backward or forward? part I: Inotropic infusion during hospitalization. Circulation. 2003;108:367-372.
12. Goldberg LI. Dopamine-clinical uses of an endogenous catecholamine. N Engl J Med. 1974; 291:707-710.
13. Goldberg LI, Hsieh YY, Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis. 1977;19: 327-340.
14. Gunnar RM, Loeb HS. Use of drugs in cardiogenic shock due to acute myocardial infarction. Circulation. 1972;45:1111-1124.
15. Stoner JD, Bolen JL, Harrison DC. Comparison of dobutamine and dopamine in treatment of sever heart failure. Br Heart J. 1977;39:536-539.
16. Lauschke A, Teichgraber UMK, Feri U, et al. Low-dose dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006;69:1669-1674.
17. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975;36:185-196.
18. Loeb HS, Bredakis J, Gunner RM. Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation. 1977;55:375-378.
19. Soran O, Feldman AM. Inotropic agents. In, Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. 2nd ed. Hosenpud J, Greenberg BH. Philadelphia: Lippincott Williams & Wilkins; 2000.
20. Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional effects of dopamine patients with cardiomyopathic heart failure. Circulation. 1977;56:468-472.
21. Dei Cas L, Metra M, Visioli O. Clinical pharmacology of inodilators. J Cardiovasc Pharmacol. 1989;14:60-71.
22. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73:177.
23. Grose R, Strain J, Greenberg M, et al. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol. 1986;7:1107-1113.
24. Dies F. Intermittent dobutamine in ambulatory patients with chronic cardiac failure. Br J Clin Pract. 1986;45:37-40.
25. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 1991;325:1468-1475.
26. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339:1810-1816.
27. Abraham WT, Adams KF, Fonarow GC, et al. Inhospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
28. Elkayam U, Karaalp IS, Wani OR, et al. The role of organic nitrates in the treatment of heart failure. Prog Cardiovascular Dis. 1999;41:255-264.
29. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol. 1990;77:41-51.
30. Classer SP. Clinical mechanism of nitrate action. Am J Cardiol. 1998;81:49-53.
31. Elkayam U, Bitar F, Akhter MW, et al. Intravenous nitroglycerine in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Therapeut. 2004;9:227-241.
32. Elkayam U, Roth A, Kumar A, et al. Haemodynamic and volumetric effects of venodilation with nitroglycerine in chronic mitral regurgitation. Am J Cardiol. 1987;60:1106-1111.
33. Dakak N, Makhoul N, Merdler A, et al. Haemodynamic and neurohormonal effects of flosequinan in sever heart failure: Similarities and differences compared with intravenous nitroglycerine therapy. Eur Heart J. 1993;14:836-844.
34. Webster MW, Sharpe DN, Coxon R, et al. Effects of reducing atrial pressure on a trial natriuretic factor and vasoactive hormonal in congestive heart failure secondary to ischemic and non ischemic cardiomyopathy. Am J Cardiol. 1989;63: 217-221.
35. Loh E, Elkayam U, Cody R, et al. A randomized, multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerine in patients with advanced heart failure. J Card Fail. 2001;7:114-121.
36. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of acute CHF). Intravenous nesiritide vs nitroglycerine for the treatment of decompensated congestive heart failure a randomized controlled trial. JAMA. 2000;287:1531-1540.
37. Elkayam U, Akther MW, Singh H, et al. Comparison of effects of left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerine in patients with decompensated heart failure. Am J Cardiol. 2004;93:237-240.
38. Munzel T, Hink U, Yigit H, et al. Role of superoxide dismutase in vivo and in vitro nitrate tolerance. Br J Pharmacol. 1999;127:1224-1230.
39. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross tolerance. J Clin Invest. 1995;95:187-194.
40. Dupuis J, Lalonde O, Lemieux R, et al. Tolerance to intravenous nitroglycerine in patient with congestive heart failure: Role of intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923-931.
41. Dakak N, Makhoul N, Flugelman MY, et al. Failure of Captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990;66:608-613.
42. Sage PR, De LL, Stafford I, et al. Nitroglycerin tolerance in human vessel: evidence for impaired nitroglycerine bio-conversion. Circulation. 2000;102:2810-2815.
43. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804.
44. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to haemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
45. Watanabe H, Kakihana M, Ohtsuka S, et al. Preventive effects Carvedilol on nitrate tolerance- a randomized, double-blind, placebo-controlled comparative study between Carvedilol and arotinolol. J Am Coll Cardiol. 1998;32:1201-1206.
46. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natiuretic peptide infusions in patients with congestive heart failure. Circulation. 1996;94:3184-3189.
47. Mills RM, Lejemtel TH, Horton DP, et al. Sustained hemodynamic effects of nesiritide (human B-type natriuretic peptide) in heart failure, a randomized, double blind, placebo clinical trial. The Natrecor Study Group. J Am Coll Cardiol. 1999;34:155-162.
48. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
49. La Villa G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Endocrinol Metab. 1994;78:1166-1171.
50. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusions in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
51. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (London). 1999;96:5-15.
52. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
53. Chow SL, Peng JT, Okamoto MP, Heywood JT. Effect of nesiritide infusion duration on renal function in acute heart failure patients. Ann Pharmacother. 2007;4:556-561.
54. Heywood JT, Ho A, Mathur V. Favourable renal hemodynamics effects of intra-renal nesiritide infusion in heart transplant patients. J Card Fail. 2006;12:S3.
55. Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. J Card Fail. 2004;10:S88.
56. Patel J, Heywood JT. B-type natriuretic peptides in heart failure. In: Yancy CW, Young JB, eds. Therapeutic Strategies in Heart Failure. Oxford: Clinical Publishing; 2007.
57. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide inpatients with acutely de-compensated heart failure. Circulation. 2005;111:1487-1491.
58. Abraham WT. Effect of baseline covariates on mortality risk in the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial. Circulation. 2005;112:11-589.
59. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007;16:134-138.
60. Mentzer RM Jr, Oz MC, Sladen SC, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol. 2007;49:716-726.
61. Yancy CW, Krum H, Massie BM, et al. The second follow up of serial infusion of nesiritide (Fusion II) trial for advance heart failure: study rationale and design. Am Heart J. 2007;153:478-484.
62. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2205;293:1900-1905.
63. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk. Circulation. 2005;112:II-676.
64. Capomolla S, Ceresa M, Pinna G, et al. Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management. Eur J Heart Fail. 2005;7:624-630.
65. Nava S, Carbone G, DiBattista N, et al. Noninvasive ventilation in cardiogenic pulmonary edema. A multicenter randomized trial. Am J Respir Crit Care Med. 2003;168:1432-1437.
66. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
67. Rose EA, Gelijns AC, Moskowitz AJ, et al; (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
68. Khot UN, Mishra M, Yamani MH, et al. Severe renal dysfunction complicating cardiogenic shock is not a contraindication to mechanical support as a bridge to cardiac transplant. J Am Coll Cardiol. 2003;41:381-385.
69. Heywood JT. The cardiorenal syndrome: lessons learned from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195-201.
70. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39:10-21.
71. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet. 1988;1:1033-1035.
72. Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J. 1991;121:1974-1983.
73. Bramlage P, Thoenes M, Paar WD, et al. Albuminuria: an indicator of cardiovascular risk. Med Klin (Munich). 2007;102:833-843.
74. Costanzo MR, Guglin ME, Saltezberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;47:675-683.
75. Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N Engl J Med. 1991;325:1825-1830.